Gold prices edge lower; heading for weekly losses ahead of U.S.-Russia talks
In a recent transaction, Bradley Sitko, Chief Investment Officer of XOMA Royalty Corp (NASDAQ:XOMA), acquired 2,000 depositary shares of the company's 8.375% Series B Cumulative Stock. The purchase, executed on April 7, 2025, was made at an average price of $24.70 per share, totaling approximately $49,400. With the current stock price at $20.19, the shares are trading below Sitko's purchase price. According to InvestingPro analysis, XOMA appears fairly valued based on its proprietary Fair Value model.
Following this acquisition, Sitko's direct ownership of these depositary shares increased to 5,045. Additionally, Sitko holds various other positions in XOMA's stock, including common stock and preferred stock, both directly and indirectly through a 401(k) plan, spouse, and children. The company, with a market capitalization of $251 million, maintains a strong financial position with a current ratio of 5.15 and impressive revenue growth of 499% in the last twelve months.
XOMA Royalty Corp, based in Emeryville, California, is part of the pharmaceutical preparations industry. The company continues to focus on life sciences, with Sitko playing a significant role in its investment strategies. Analysts maintain a bullish outlook, with price targets ranging from $55 to $104 per share. For deeper insights into insider trading patterns and comprehensive financial analysis, check out InvestingPro, which offers exclusive metrics and real-time alerts.
In other recent news, XOMA Ltd . has been the focus of several analyses by H.C. Wainwright, which maintained a Buy rating on the company with a revised price target of $104. This adjustment from a previous target of $123 was due to the exclusion of iscalimab from financial projections. Despite the earnings miss, with a GAAP EPS of ($1.65) compared to an estimated ($0.40), and revenues of $28.5 million falling short of the $30.8 million forecast, the firm remains optimistic about XOMA's prospects. The company's strategic transactions, including acquisitions and royalties from products like Vabysmo and Ojemda, are highlighted as key revenue drivers. Vabysmo alone generated $2.94 billion in sales, contributing a 0.5% royalty to XOMA. The company's cash position remains strong at $106.8 million, despite financial challenges. Analysts note that XOMA's diversified royalty portfolio provides a buffer against potential negative developments in partnered programs. This approach is seen as a significant strength, offering protection against the volatility of clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.